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Abstract
Background: Type 2 diabetes mellitus (T2DM) is a genetically heterogeneous disease, hepatocyte
nuclear factor-1 homeobox A (HNF1A) single-nucleotide polymorphisms (SNPs) playing a minor
role in its pathogenesis. HNF1A is a frequent cause of monogenic diabetes, albeit with early-onset.
Some uncommon subgroups like late-onset autosomal dominant diabetes mellitus (LOADDM) may
present peculiar inheritance patterns with a stronger familial component. This study aims to
investigate the relationship of HNF1A SNPs with cardiovascular risk factors in this group, as well as
to characterize them in contrast with classical T2DM (CT2DM).
Methods: eighteen LOADDM (age at onset > 40 y.o.; diabetes in 3 contiguous generations,
uniparental lineage) along with 48 CT2DM patients and 42 normoglycemic controls (N group) have
been evaluated for cardiovascular risk factors and SNPs of HNF1A.
Results: LOADDM showed significantly higher frequencies of SNPs A98V (22.2% vs 2.1%, p =
0.02) and S487N (72.2% vs 43.8%, p = 0.049) of HNF1A compared to CT2DM. I27L did not show
significant difference (66.7% vs 45.8%), but associated with lower risk of hypertriglyceridemia (OR
0.16, 95% CI 0.04–0.65, p = 0.01). "Protective effect" was independent from other well-known
predictive risk factors for hypertriglyceridemia, such as waist circumference (OR 1.09 per 1 cm
increase, p = 0.01) and HDL (OR 0.01 per 1 mmol/l, p = 0.005), after logistic regression.
Conclusion: Late onset autosomal dominant diabetes mellitus is clinically indistinguishable from
classical type 2 diabetes individuals. However, LOADDM group is enriched for common HNF1A
polymorphisms A98V and S487N. I27L showed "protective effect" upon hypertriglyceridemia in
this sample of individuals, suggesting a role for HNF1A on diabetic individuals' lipid profile. These
data contribute to the understanding of the complex interactions between genes, hyperglycemia
and cardiovascular risk factors development in type 2 diabetes mellitus.
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Type 2 diabetes mellitus (T2DM) is a clinically and genet-
ically heterogeneous disease. The spectrum of T2DM
ranges from lean and predominantly insulin-deficient
individuals, to those more obese and insulin resistant [1].
Associated clinical conditions such as dyslipidemia,
hypertension and visceral obesity, components of the
Metabolic Syndrome (MS), further contribute to this het-
erogeneity.
Important advancements in the understanding of the
genetic bases of T2DM have arisen in the last few years
and several genes have now been associated to this dis-
ease. However, complete knowledge about the interaction
among involved genes is still lacking. Curiously, most
T2DM genes with previously known function are associ-
ated to insulin deficiency rather than insulin resistance
(IR), as believed in the past decades [2].
MODY is a group of monogenic forms of diabetes, charac-
terized by early onset and autosomal dominant inherit-
ance, caused by mutations in 6 known genes. The most
common are glucokinase (GCK) and hepatocyte nuclear
factor-1 homeobox A (HNF1A), responsible for MODY2
and MODY3, respectively [3]. Effect of variants in these
genes (or in their corresponding regions) upon T2DM has
been demonstrated in genome-wide association studies
[4,5]. This association is of small magnitude, as in most
other T2DM genes. Families with clinical features of
MODY but without mutations detected in any of the six
known genes (termed MODYX) may phenotypically over-
lap with T2DM. MODYX individuals show greater age at
diagnosis of diabetes than MODY and IR features such as
obesity and dyslipidemia [6]. MODYX has been shown to
be genetically heterogeneous, familial clustering of diabe-
tes occurring either due to several unknown monogenic
forms or by chance in a polygenic setting [7].
The involvement of HNF1A polymorphisms with MS has
already been investigated in normal individuals [8-11],
namely the Isoleucine to Leucine substitution on codon
27, located in exon 1, but with conflicting results. One
study with a sample of Japanese individuals demonstrated
a protective effect, with progressive higher levels of HDL-
cholesterol with one and two Leucine alleles when com-
pared to Isoleucine homozygotes [11]. Other study
showed beta-cell function diminution which was progres-
sive according to the number of Leu copies [10], and
another demonstrated heterozygotes to have higher insu-
lin sensitivity than both Ile and Leu homozygotes, albeit
in an ethnically heterogeneous sample [9]. However, if
the relationship of this variant with MS is still present in
diabetes mellitus has not been as thoroughly investigated.
Besides, the majority of studies approaching prevalence of
this and other variants have been done in European and
Japanese populations [12-19]. Brazilian population is one
of the most heterogeneous in the world, with intense
admixture among European, African and native Brazilian
populations [20]. Moreover, MODYX appears to be more
prevalent in Brazil than in European populations [21,22].
A more homogeneous group of type 2 diabetic individu-
als, as one with familial clustering, would be adequate to
perform these studies in a heterogeneous population like
this. Some uncommon T2DM families may show a strict
autosomal dominant clinical pattern of inheritance, but
with late onset typical of classical T2DM. Despite various
reports studying familial clustering models as trios and
multiplex families [23,24], this specific model has not
been studied to our knowledge. Although the possibility
that MODY mutations have a causal role in this group is
remote, the exclusion of the most common MODY muta-
tions by sequencing the whole HNF1A and GCK genes is
necessary given the peculiar inheritance and onset pat-
terns. A possible role for unknown variants in these indi-
viduals has also to be considered. These altogether grant
investigation of characteristics that could individualize
approach to this group regarding T2DM treatment. Since
previous studies linked HNF1A variants to MS in normal
individuals, investigating if this relationship persists in
T2DM is appropriate.
This study aims to verify the frequency of exonic HNF1A
variants in Brazilian individuals with late-onset auto-
somal dominant diabetes mellitus and classical T2DM, as
well as to characterize its relationship to cardiovascular
risk factors.
Methods
Individuals with autosomal dominant (3 contiguous gen-
erations of familial history and uniparental lineage) and
late-onset diabetes (age > 40 years old) have been studied,
being arbitrarily denominated late-onset autosomal dom-
inant diabetes mellitus (LOADDM) group. To differenti-
ate them form classical MODY, late onset had to be
present in all diabetic members of the family. Approxi-
mately 500 individuals from the Outpatient Diabetes
Clinic at the Federal University of Sao Paulo have been
screened for the inclusion criteria, eighteen individuals
from 15 families meeting the criteria for the LOADDM
group. Forty-eight unrelated individuals with classical
T2DM (late-onset, any kind of familial history except
either the one defining LOADDM group or both parents
with diabetes) have been included as controls and
denominated CT2DM group. All diabetic patients were
included only if HbA1c values were below 8%, to avoid
influence of severe beta cell dysfunction on the cardiovas-
cular risk factors evaluated. Forty-two normoglycemic
controls (N group) have been studied as well. Inclusion
criteria for the N group were fasting blood glucose belowPage 2 of 9
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tives. The study has been approved by the Ethics Commit-
tee of the Federal University of Sao Paulo, and informed
written consent was obtained from all participants.
Cardiovascular Risk Factors
Patients underwent complete physical examination and
anthropometric evaluation. Blood pressure (BP) was
measured with a mercury sphygmomanometer. Weight
was measured with a clinical scale and stature with a sta-
diometer. BMI was calculated by dividing weight in kg by
the square of height in meters. Waist circumference was
measured at the midpoint between the rib cage and the
iliac crest, determined along the median axillary line.
Obesity was defined as a BMI ≥ 30 kg/m2 and overweight
as BMI ≥ 25 kg/m2 (including those above 30 kg/m2). Met-
abolic syndrome components were evaluated by the
NCEP-ATPIII criterion, two or more of them being diag-
nostic in diabetic patients (or three in the N group) [25].
Laboratory methods
After a 12-hour fast, three blood samples with a 5-minute
interval between each of them have been drawn, for C-
peptide determination. Fasting blood glucose (FBG),
HbA1c, total cholesterol, HDL-cholesterol, triglycerides,
and anti-glutamic acid decarboxylase antibodies (GADA)
have been analyzed in one of the samples. LDL-choles-
terol has been calculated by Friedewald's equation. The
following laboratory methods have been employed:
-Biochemistry
glucose-oxidase method has been used for FBG, colori-
metric method for lipid profile and alkaline picrate for
creatinine, using Bayer ADVIA 1650 automatic analyzer
(Bayer Corp, Tarrytown, NY, USA). HbA1c was measured
by HPLC (normal value: 4–6%).
-C-peptide
IFMA (autoDELFIA, Turku, Finland). Normal range (NR)
1.19–18.9 pmol/L and sensitivity 0.156 pmol/L pmol/L.
-GADA
radio-immunoassay (RSR Limited, Cardiff, UK) with 125-
iodine-marked human recombinant GAD. Intra-assay var-
iation coefficient 3.6% (4.2 U/mL); 2.9% (27.2 U/mL).
Inter-assay variation coefficient 3.6% (4.2 U/mL); 5.1%
(25.0 U/mL). Normal cut-off value 1.72 U/mL, corre-
sponding to the 99th percentile of a sample of 194 normal
individuals assessed at the Federal University of São Paulo
Endocrinology Laboratory [26].
Genetic analysis
Leukocyte DNA has been extracted from whole blood col-
lected in EDTA tubes, employing commercially available
kits (Gentra Systems, Minneapolis, MN, USA). In the
LOADDM group, all exons and promoters of HNF1A and
GCK have been amplified by PCR, utilizing Promega PCR
Mastermix (Promega Corporation, Madison, WI, USA)
and previously described primers [15]. PCR was per-
formed according to previously described conditions [27].
Amplicons have been directly sequenced using BigDye 3.1
Sequence Termination kit in ABI3100 Genetic Analyzer
(Applied Bio Systems, Foster City, CA, USA). All exons
containing non-synonymous single-nucleotide polymor-
phisms (SNPs) have been sequenced in both CT2DM and
N individuals.
Homeostasis model assessment (HOMA) calculations
HOMA-%B and HOMA-IR calculations have been per-
formed only in individuals not taking insulin, using fast-
ing blood glucose and C-peptide values, with HOMA
Calculator version 2.2.1 computer software [28].
Statistical analyses
Patients have been divided in three groups as stated above
(LOADDM, CT2DM and N). One-way ANOVA with Bon-
ferroni correction has been employed to compare contin-
uous variables and χ2 for categorical ones. Non-normally
distributed data have been normalized by logarithmic
transformation. Pearson's correlation was used for contin-
uous variables within groups. Diabetic patients have also
been divided in groups according to genetic variants
encountered and analyzed by Student's T-test and χ2. Var-
iables with significant differences in univariate analysis
were entered in Forward Logistic Regression (LR) models
with Wald statistics. Hosmer-Lemeshow test was used for
goodness-of-fit. In this test, observed values are compared
to expected values obtained by the model. The higher the
value of p is (less significant), better the fit of the model.
Statistical power of LR models has been calculated post-
hoc. Values of continuous variables are expressed in mean
± SD (or median and interquartile interval when not nor-
mally distributed), and categorical ones in percentages. A
value of p < 0.05 (two-tailed) was considered significant.
All analyses have been carried out in SPSS 13.0 for Win-
dows software (SPSS Inc., Chicago, IL, USA), except for
post-hoc LR power calculations, performed on PASS 2008
software version 08.0.5 (NCSS LLC, Kaysville, UT, USA).
Results
No mutations or polymorphisms of GCK have been
encountered in our sample. No HNF1A mutations causa-
tive of MODY have been found, as well. Three common
non-synonymous SNPs of HNF1A have been found, two
of them with a significantly higher prevalence in
LOADDM group compared to CT2DM, as shown on Table
1. All SNPs were in Hardy-Weinberg equilibrium. I27L
and S487N were in linkage disequilibrium (LD), with r2 =
0.64. Anthropometric features, along with cardiovascular
risk factors and MS prevalence, are detailed in Table 2.Page 3 of 9
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Table 1: Frequencies of HNF1A SNPs I27L (rs1169288), A98V (rs1800574) and S487N (rs2464196) in the studied groups.
genotypes CT2DM1 LOADDM2 N3 p4
n 48 18 42
I27L (rs1169288) II (%) 54.2 33.3 42.9
IL+LL (%) 45.8 66.7 57.1 NS
A98V (rs1800574) AA (%) 97.9 77.8 92.9
AV+VV (%) 2.1 22.2 7.1 0.02
S487N (rs2464196) SS (%) 56.2 27.8 35.7
SN+NN (%) 43.8 72.2 64.3 0.049
1classical type 2 diabetes mellitus, 2late-onset autosomal dominant diabetes mellitus, 3normoglycemic; 4two degrees-of-freedom significance
Table 2: Characteristics of studied groups
p
CT2DM LOADDM N N vs CT2DM N vs LOADDM
n 48 18 42 NS NS
age (years) 65.6 ± 7.1 67.4 ± 10.8 63.0 ± 11.2 NS NS
age at diagnosis (years) 54.9 ± 8.4 54.7 ± 10.0 - - -
weight (kg) 73.2 ± 13.7 73.4 ± 15.3 61.4 ± 13.4 <0.01 <0.05
BMI (kg/m2) 28.7 ± 4.2 28.5 ± 4.3 25.3 ± 3.7 <0.01 <0.05
waist (cm) 98.7 ± 10.7 99.4 ± 13.0 86.3 ± 9.9 <0.01 <0.01
Systolic BP (mmHg) 125.3 ± 16.0 118.0 ± 13.6 130.1 ± 17.3 NS <0.05
Diastolic BP (mmHg) 75.2 ± 7.6 72.6 ± 8.7 81.8 ± 9.0 <0.01 <0.01
FBG (mmol/l) 7.18 ± 1.69 6.41 ± 1.91 4.98 ± 0.33 <0.01 <0.01
A1c (%) 6.4 ± 2.4 7.4 ± 1.2 5.5 ± 0.6 0.07 <0.01
total cholesterol (mmol/l) 4.44 ± 0.87 4.56 ± 0.97 4.94 ± 1.04 <0.05 NS
HDL-cholesterol (mmol/l) 1.23 ± 0.35 1.18 ± 0.28 1.43 ± 0.43 <0.05 0.07
LDL-cholesterol (mmol/l) 2.35 ± 0.64 2.64 ± 0.86 2.96 ± 0.84 <0.01 NS
triglycerides (mmol/l) 1.45 (1.07–2.07) 1.36 (1.05–1.84) 1.14 (0.78–1.48) <0.05 NS
HOMA-%B1 77.1 ± 42.7 80.5 ± 46.1 107.8 ± 40.0 <0.01 NS
HOMA-IR1 2.12 ± 1.28 2.43 ± 1.39 1.27 ± 0.64 <0.05 NS
fasting C-peptide (nmol/l) 0.78 ± 0.50 0.77 ± 0.56 0.57 ± 0.29 NS NS
p2
females (%) 68.8 72.2 83.3 NS
hypertension (%) 85.4 72.2 50 <0.01
obesity (%) 31.3 22.2 11.9 NS
overweight (%) 83.3 66.7 52.4 <0.01
central obesity (%) 62.5 61.1 38.1 0.051
low HDL (%) 63.8 50 34.1 <0.05
hypertriglyceridemia (%) 38.8 33.3 17.7 NS
dyslipidemia treatment (%)3 8.3 0 7.1 NS
metabolic syndrome (%) 87.5 77.8 11.9 <0.01
insulin treatment (%)4 14.9 37.5 - 0.054
positive GADA (%) 4.9 0 2.6 NS
1calculated in 39 individuals from group CT2DM, 14 from LOADDM, and 39 from N; 2Two df significance, except 4(one df); 3current or previous 
use of fibrates/statins; NS denotes p< 0.10
Cardiovascular Diabetology 2009, 8:28 http://www.cardiab.com/content/8/1/28There were no significant differences between LOADDM
and CT2DM groups.
Diabetic patients (i.e., only those from LOADDM and
T2DM groups) have been divided in two groups according
to I27L genotype, utilizing a dominant model, that is,
group II (containing only Isoleucine homozygous indi-
viduals) and group IL+LL (containing both heterozygous
and homozygous carriers of the Leucine allele). Compari-
son between groups is illustrated in table 3. No differences
were observed in age, age at diagnosis, weight, BMI, waist
circumference, FBG, HbA1c, blood pressure and lipid pro-
file (as continuous variables). There were no differences
between groups divided according to S487N genotype (SS
and SN+NN) for the same comparisons (data not shown).
Dividing normal individuals in the same way, no differ-
ences have been observed between the two groups, for
both SNPs.
Prevalence of hypertriglyceridemia was significantly lower
in individuals with the I27L SNP as compared to those
without. Despite II and IL+LL groups differed only in
hypertriglyceridemia in univariate analysis, patients with
hypertriglyceridemia (regardless of genotype) were differ-
ent from those with normal triglyceride levels in the com-
monly expected aspects: longer time from diagnosis of
diabetes; higher mean waist circumference and percentage
of insulin treated patients; lower mean HDL levels (and
also higher prevalence of low HDL). These variables along
with presence of I27L were entered as independent varia-
bles in a forward LR model, with hypertriglyceridemia as
dependent variable, aiming at achieving highest good-
ness-of-fit (g.o.f.) and statistical power greater than 80%.
HDL has been entered either as a continuous or categori-
cal variable. Besides waist circumference, other measure-
ments of adiposity have been entered (weight, BMI, or
corresponding categorical variables). Gender was also
included, since HDL and waist circumference can be con-
sidered gender-specific. Results are expressed in Table 4.
From the three models depicted with power > 80%,
Model 1 showed the best fit.
None of the variables entered in the regression models
showed multicollinearity among themselves, although
time from diagnosis was longer in individuals taking insu-
lin. Variables such as age, HbA1c, presence of hyperten-
sion, use of lipid medication, and belonging to the
LOADDM group did not influence association of hyper-
triglyceridemia to I27L (data not shown). Excluding
LOADDM patients from analysis, similar findings
resulted.
Although triglyceride levels were not different between
groups Ile and Leu as a continuous variable, they corre-
lated moderately to adiposity measurements only in II (r
0.43, p = 0.02), but not in IL+LL (r 0.04, p = 0.84) group.
Analogously, the same correlation occurred in CT2DM
group (r 0.34, p = 0.02), but not in LOADDM (r -0.34, p
= 0.20), and in SS group (r 0.53, p = 0.002), but not in
SN+NN (r -0.15, p = 0.41) group.
Discussion
Variants of HNF1A were associated to late-onset auto-
somal dominant diabetes mellitus (LOADDM) and mod-
ified the relationship between plasma triglyceride levels
and waist circumference in Brazilian individuals with
T2DM. The LOADDM group is enriched for common
HNF1A polymorphisms A98V and S487N, although fit-
ting within the heterogeneity of classical T2DM, being
clinically indistinguishable from it. Furthermore, the pres-
ence of I27L variant in both LOADDM and CT2DM can
show "protective effect" on the risk of hypertriglyceri-
demia afforded by its known predictive factors.
Higher frequencies of two SNPs not known to be in LD
[4,18] were found in the LOADDM group, pointing to
genetic differences between this group and classical
T2DM. Besides, classical MODY has been excluded by
complete sequencing of HNF1A and GCK genes. Never-
theless, in spite of I27L and S487N being in LD, we did
not duplicate the same findings with both SNPs. A higher
frequency of I27L in the LOADDM group would probably
occur with an accordingly powered sample, but the rarity
of individuals with this particular inheritance pattern pre-
cluded this task. However, studying pooled diabetic
patients regarding presence of the I27L polymorphism,
lower prevalence of hypertriglyceridemia in individuals
with this SNP was seen. This finding has not been previ-
ously described. Protective effect of I27L on hypertriglyc-
eridemia, with an OR in the order of 0.16, was significant
in our sample even after correction for possible confound-
ers. It occurred independently of other features already
known to correlate with triglyceride levels such as time
Table 3: Characteristics of diabetic patients (grouped LOADDM 
and CT2DM individuals) according to I27L polymorphism 
genotype.
II IL+LL p
females (%) 71.9 67.6 NS
hypertension (%) 90.3 76.5 NS
obesity (%) 25 33.3 NS
overweight (%) 75 84.8 NS
central obesity (%) 59.4 64.7 NS
low HDL (%) 64.5 55.9 NS
hypertriglyceridemia (%) 74.2 50 0.045
dyslipidemia treatment (%)1 28.1 26.5 NS
metabolic syndrome (%) 90.6 79.4 NS
insulin treatment (%) 22.6 23.5 NS
positive GADA (%) 3.6 3.6 NS
1current or previous use of fibrates/statinsPage 5 of 9
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over, the first two variables showed suppressive effect
upon I27L, which intensified statistical power of the asso-
ciation seen on univariate analysis.
Prevalence of I27L, A98V, and S487N in type 2 diabetic
patients and normal controls has been widely studied in
various European and Asian populations [12-19]. Overall,
frequency of these three SNPs in our sample does not
seem remarkably different from other populations, which
fall mostly in the 40 to 50% range for I27L [10] and at the
3 to 7% range for A98V [12,18]. Data on prevalence of
S487N are slightly underrepresented in literature, since it
is commonly in strong LD with I27L, but their prevalence
is similar [4,18]. Frequency of A98V and S487N in
LOADDM group seems to deviate both from our controls
groups and other populations. A similar finding has been
reported only in a South Indian population, when a 20%
or greater frequency of A98V occurred in individuals both
with autosomal inheritance pattern and without familial
history, albeit in individuals with early-onset type 2 diabe-
tes. The pathophysiology of this specific T2DM subtype is
poorly understood [30].
Our findings for I27L and hypertriglyceridemia are analo-
gous to data previously reported for HDL [11], which is in
accordance to a known pathophysiological connection
[28] between both lipid subtypes. Among the different
cardiovascular risk factors with a well-studied association
to I27L [9-11], none of them occurred consistently, how-
ever they showed a common trend of protective effect
upon MS and IR associated traits in non-diabetic individ-
uals. These effects have not been similarly demonstrated
in diabetic patients, but a subsequent publication show-
ing subjects from the Botnia study to be more insulin-sen-
sitive in presence of I27L [18] supports this hypothesis.
The suppressive effect of adiposity measurements upon
association of I27L and hypertriglyceridemia seen in our
sample complements previous findings showing waist-to-
hip ratio to act as a covariate on the association between
I27L and IR [9]. Higher HDL levels are also associated to
other variants of HNF1A, such as the G319S polymor-
phism private of the Oji-Cree population [31], reinforcing
the role of HNF1A on lipid abnormalities associated to
the MS. Interestingly, although I27L association with
T2DM has been approached by several large sample stud-
Table 4: Logistic regression models testing association of hypertriglyceridemia and I27L in diabetic patients (grouped LOADDM and 
CT2DM individuals).
Dependent variable: hypertriglyceridemia
Independent variable1 OR (exp B) 95% C.I. p p for g.o.f.2 power (%)
MODEL 1
I27L 0.16 0.04–0.65 0.011 0.78 91.6
time from diagnosis (years) 1.23 1.04–1.46 0.013
waist circumference (cm) 1.09 1.02–1.17 0.014
HDL (mmol/l) 0.01 0.001–0.26 0.005
(insulin use)
(female gender)
constant 0.02 0.260
MODEL 2
I27L 0.19 0.05–0.73 0.016 0.36 87.1
waist circumference (cm) 1.09 1.02–1.17 0.018
time from diagnosis (years) 1.16 1.02–1.32 0.023
low HDL 9.52 2.36–38.45 0.002
(female gender)
constant 0.02 0.255
MODEL 3
I27L 0.17 0.04–0.69 0.013 0.29 88.5
waist circumference (cm) 1.09 1.02–1.17 0.016
time from diagnosis (years) 1.15 1.01–1.31 0.033
low HDL 8.89 2.21–35.78 0.002
(female gender)
(insulin use)
constant 0.00 0.008
1variables between brackets have been included but did not enter the model upon analysis; 2goodness-of-fitPage 6 of 9
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been correspondingly addressed.
Higher frequencies of A98V and S487N in LOADDM
group are probably a specific feature of this subset of type
2 diabetic patients, since CT2DM and N groups showed
frequencies similar to other populations, but might also
stem from differences among them. Given the scarcity of
these families, this could possibly occur in other ethnic
groups but would be diluted in the whole T2DM popula-
tion. Absence of GCK variants in our sample is not surpris-
ing, since there are no exonic variants as common as those
encountered in HNF1A [32].
Since the majority of previous data about I27L and MS
traits has been drawn from Asian and European samples,
differences among studied populations are a possible
explanation for the association of I27L and hypertriglycer-
idemia in our study. Since I27L is very rare in African pop-
ulations [33], but Brazilian individuals described as
Caucasians might carry up to 28% of African ancestry
markers [20], this variant could be modulated by a differ-
ent set of genetic traits in European and Brazilian popula-
tions.
Suppressive effect of adiposity measurements upon "pro-
tective" effect of I27L on hypertriglyceridemia raises the
hypothesis that I27L could be preventing central obesity
from increasing IR, although mechanisms linking I27L
and IR are largely unknown [18]. The expected positive
correlation between triglycerides and measurements of
adiposity [34] occurred in patients without I27L and
S487N polymorphisms, and analogously in the CT2DM
group. Conversely, correlations were absent in individuals
carrying the SNPs and also in LOADDM group. These facts
altogether support this view, but at the same time raise the
question whether the contribution of I27L to hypertriglyc-
eridemia, despite being independent of other cardiovas-
cular risk factors, is dependent on inheritance pattern.
Autosomal dominant inheritance did not enter any of the
LR models, and the same models applied only to CT2DM
patients brought essentially the same results for hypertrig-
lyceridemia. Besides, the fact that S487N was more preva-
lent in the LOADDM group, but did not associate with
cardiovascular risk factors, may point to an independent
role of I27L.
HNF1A mutated with variants I27L, A98V and S487N has
been demonstrated to have decreased transcriptional
activity upon genes involved in glucose metabolism
(GLUT-2). This transcriptional impairment is situated
midway between normal and MODY causative mutations
[18]. Nevertheless, genes encoding other proteins
involved in lipid metabolic pathways (such as 3-hydroxy-
3-methylglutaryl coenzyme A reductase, for example) are
also known targets for HNF1A [35]. Interaction of HNF1A
with lipid hepatic metabolism in diabetes has been object
of relatively little study, and mostly in MODY individuals
[36]. In spite of I27L and S487N similar transcriptional
impairment, the first is probably accountable for the
described phenotypes, since it is located in the dimeriza-
tion domain, a highly conserved region of the HNF1A
gene, with greater functional significance [35]. An indirect
effect of other SNPs such as S487N through LD, although
not totally excluded, is unlikely.
Conclusion
These data show a group of late-onset autosomal domi-
nant diabetic individuals enriched for HNF1A polymor-
phisms, despite being clinically indistinguishable to
classical T2DM. Concurrently, we report "protective"
association of I27L, a common polymorphism of HNF1A,
to hypertriglyceridemia in a sample of Brazilians with
T2DM. This finding, along with other previously
described evidence, point to a role of HNF1A in cardiovas-
cular risk factors development in adult hyperglycemic
individuals, which should be better understood through
trans-ethnic investigation in future studies. Association
studies linking this gene primarily to lipid phenotypes in
diabetes are warranted. The LOADDM group is a poten-
tially interesting model for genetic studies in T2DM, since
it could possibly represent a concentration of diabetes
polygenes in the same individuals in a degree greater than
would be expected by chance alone.
Abbreviations
BP: blood pressure; CT2DM: classical type 2 diabetes mel-
litus; FBG: fasting blood glucose; IR: insulin resistance;
LD: linkage disequilibrium; LOADDM: late-onset auto-
somal dominant diabetes mellitus; LR: logistic regression;
MS: metabolic syndrome; N: normoglycemic; SNP: single
nucleotide polymorphism.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
FMAG carried out the molecular genetic studies, partici-
pated in the sequence alignment, participated in the
design of the study, performed the statistical analysis and
drafted the manuscript. GKF carried out the molecular
genetic studies and participated in the sequence align-
ment. TSK carried out the immunoassays and molecular
genetic studies. MMO participated in the selection and
clinical evaluation of the patients. AFR and SAD con-
ceived of the study, participated in its design, coordina-
tion and patient selection, and helped to draft the
manuscript. All authors read and approved the final man-
uscriptPage 7 of 9
(page number not for citation purposes)
Cardiovascular Diabetology 2009, 8:28 http://www.cardiab.com/content/8/1/28Acknowledgements
This paper has been supported by grant number 03/12419-4 from Fundação 
de Amparo à Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, Brazil.
References
1. Birkeland KI, Kilhovd B, Thorsby P, Torjensen PA, Ganss R, Vaaler S,
Hanssen KF: Heterogeneity of non-insulin-dependent diabetes
expressed as variability in insulin sensitivity, beta-cell func-
tion and cardiovascular risk profile.  Diabet Med 2003, 20:37-45.
2. Frayling TM, McCarthy MI: COMMENTARY: Genetic studies of
diabetes following the advent of the genome-wide associa-
tion study: where do we go from here?  Diabetologia 2007,
50:2229-2233.
3. Giuffrida FMA, Reis AF: Genetic and clinical characteristics of
maturity-onset diabetes of the young.  Diabetes Obes Metab
2005, 7:318-326.
4. Winckler W, Burtt NP, Holmkvist J, Cervin C, de Bakker PIW, Sun
M, Almgren P, Tuomi T, Gaudet D, Hudson TJ, Ardlie KG, Daly MJ,
Hirschhorn JN, Altshuler D, Groop L: Association of Common
Variation in the HNF1alpha Gene Region With Risk of Type
2 Diabetes.  Diabetes 2005, 54:2336-2342.
5. Winckler W, Weedon MN, Graham RR, McCarroll SA, Purcell S,
Almgren P, Tuomi T, Gaudet D, Boström KB, Walker M, Hitman G,
Hattersley AT, McCarthy MI, Ardlie KG, Hirschhorn JN, Daly MJ,
Frayling TM, Groop L, Altshuler D: Evaluation of Common Vari-
ants in the Six Known Maturity-Onset Diabetes of the Young
(MODY) Genes for Association With Type 2 Diabetes.  Dia-
betes 2007, 56:685-693.
6. Doria A, Yang Y, Malecki M, Scotti S, Dreyfus J, O'Keeffe C, Orban T,
Warram JH, Krolewski A: Phenotypic Characteristics of Early-
Onset Autosomal-Dominant Type 2 Diabetes Unlinked to
Known Maturity-Onset Diabetes of the Young (MODY)
Genes.  Diabetes Care 1999, 22:253-261.
7. Frayling TM, Lindgren CM, Chevre JC, Frayling TM, Lindgren CM,
Chevre JC, Menzel S, Wishart M, Benmezroua Y, Brown A, Evans JC,
Rao PS, Dina C, Lecoeur C, Kanninen T, Almgren P, Bulman MP,
Wang Y, Mills J, Wright-Pascoe R, Mahtani MM, Prisco F, Costa A,
Cognet I, Hansen T, Pedersen O, Ellard S, Tuomi T, Groop LC,
Froguel P, Hattersley AT, Vaxillaire M: A Genome-Wide Scan in
Families With Maturity-Onset Diabetes of the Young: Evi-
dence for Further Genetic Heterogeneity.  Diabetes 2003,
52:872-881.
8. Urhammer SA, Moller AM, Nyholm B, Ekstrom CT, Eiberg H, Clausen
JO, Hansen T, Pedersen O, Schmitz O: The Effect of Two Fre-
quent Amino Acid Variants of the Hepatocyte Nuclear Fac-
tor-1a Gene on Estimates of the Pancreatic b-Cell Function
in Caucasian Glucose-Tolerant First-Degree Relatives of
Type 2 Diabetic Patients.  J Clin Endocrinol Metab 1998,
83:3992-3995.
9. Chiu KC, Chuang L-M, Ryu JM, Tsai GP, Saad MF: The I27L Amino
Acid Polymorphism of Hepatic Nuclear Factor-1a Is Associ-
ated with Insulin Resistance.  J Clin Endocrinol Metab 2000,
85:2178-2183.
10. Chiu KC, Chuang LM, Chu A, Yoon C, Wang M: Comparison of
the impact of the I27L polymorphism of the hepatocyte
nuclear factor-1alpha on estimated and measured beta cell
indices.  Eur J Endocrinol 2003, 148:641-647.
11. Babaya N, Ikegami H, Fujisawa T, Nojima K, Itoi-Babaya M, Inoue K,
Nakura J, Abe M, Yamamoto M, Jin JJ, Wu Z, Miki T, Fukuda M, Ogi-
hara T: Association of I27L Polymorphism of Hepatocyte
Nuclear Factor-1alpha Gene with High-Density Lipoprotein
Cholesterol Level.  J Clin Endocrinol Metab 2003, 88:2548-2551.
12. Urhammer SA, Rasmussen SK, Kaisaki PJ, Oda N, Yamagata K, Møller
AM, Fridberg M, Hansen L, Hansen T, BelL GI, Pedersen O: Genetic
variation in the hepatocyte nuclear factor-1a gene in Danish
Caucasians with late-onset NIDDM.  Diabetologia 1997,
40:473-475.
13. Behn PS, Wasson J, Chayen S, Smolovitch I, Thomas J, Glaser B, Per-
mutt MA: Hepatocyte Nuclear Factor 1 alpha Coding Muta-
tions Are an Uncommon Contributor to Early-Onset Type 2
Diabetes in Ashkenazi Jews.  Diabetes 1998, 47:967-969.
14. Nishigori H, Yamada S, Kohama T, Utsugi T, Shimizu H, Takeuchi T,
Takeda J: Mutations in the hepatocyte nuclear factor-1 alpha
gene (MODY3) are not a major cause of early-onset nonin-
sulin-dependent (type 2) diabetes mellitus in Japanese.  J Hum
Genet 1998, 43:107-110.
15. Lehto M, Wipemo C, Ivarsson SA, Lindgren C, Lipsanen-Nyman M,
Weng J, Wibell L, Widøn E, Tuomi T, Groop L: High frequency of
mutations in MODY and mitochondrial genes in Scandina-
vian patients with familial early-onset diabetes.  Diabetologia
1999, 42:1131-1137.
16. Rissanen J, Wang H, Miettinen R, Kärkkäinen P, Kekäläinen P,
Mykkänen L, Kuusisto J, Karhapää P, Niskanen L, Uusitupa M, Laakso
M: Variants in the hepatocyte nuclear factor-1alpha and -
4alpha genes in Finnish and Chinese subjects with late-onset
type 2 diabetes.  Diabetes Care 2000, 23:1533-1538.
17. Bonnycastle LL, Willer CJ, Conneely KN, Jackson AU, Burrill CP,
Watanabe RM, Chines PS, Narisu N, Scott LJ, Enloe ST, Swift AJ,
Duren WL, Stringham HM, Erdos MR, Riebow NL, Buchanan TA,
Valle TT, Tuomilehto J, Bergman RN, Mohlke KL, Boehnke M, Collins
FS: Common Variants in Maturity-Onset Diabetes of the
Young Genes Contribute to Risk of Type 2 Diabetes in Finns.
Diabetes 2006, 55:2534-2540.
18. Holmkvist J, Cervin C, Lyssenko V, Winckler W, Anevski D, Cilio C,
Almgren P, Berglund G, Nilsson P, Tuomi T, Lindgren CM, Altshuler
D, Groop L: Common variants in HNF-1 α and risk of type 2
diabetes.  Diabetologia 2006, 49:2882-2891.
19. Yokoi N, Kanamori M, Horikawa Y, Takeda J, Sanke T, Furuta H,
Nanjo K, Mori H, Kasuga M, Hara K, Kadowaki T, Tanizawa Y, Oka
Y, Iwami Y, Ohgawara H, Yamada Y, Seino Y, Yano H, Cox NJ, Seino
S: Association Studies of Variants in the Genes Involved in
Pancreatic Beta-Cell Function in Type 2 Diabetes in Japa-
nese Subjects.  Diabetes 2006, 55:2379-2386.
20. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena
SDJ: Color and genomic ancestry in Brazilians.  Proc Nat Acad
Sci USA 2003, 100:177-182.
21. Moises RS, Reis AF, Morel V, Chacra AR, Dib SA, Bellanne-Chantelot
C, Velho G: Prevalence of Maturity-Onset Diabetes of the
Young Mutations in Brazilian Families with Autosomal-
Dominant Early-Onset Type 2 Diabetes.  Diabetes Care 2001,
24:786-788.
22. Furuzawa GK, Giuffrida FMA, Oliveira CSV, Chacra AR, Dib SA, Reis
AF: Low Prevalence of MODY 2 and MODY 3 mutations in
Brazilian Individuals with Clinical MODY Phenotype.  Diab
Res Clin Pract 2008, 81:e12-4.
23. Frayling TM, Walker M, McCarthy MI, Evans JC, Allen LI, Lynn S,
Ayres S, Millauer B, Turner C, Turner RC, Sampson MJ, Hitman GA,
Ellard S, Hattersley AT: Parent-Offspring Trios: A Resource to
Facilitate the Identification of Type 2 Diabetes Genes.  Diabe-
tes 1999, 48:2475-79.
24. Macfarlane WM, Frayling TM, Ellard S, Evans JC, Allen LI, Bulman MP,
Ayres S, Shepherd M, Clark P, Millward A, Demaine A, Wilkin T,
Docherty K, Hattersley AT: Missense mutations in the insulin
promoter factor-1 gene predispose to type 2 diabetes.  J Clin
Invest 1999, 104:R33-R39.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults: Executive summary of the Third Report
of The National Cholesterol Education Program (NCEP)
Expert Panel on Detecton, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel
III).  JAMA 2001, 285:2486-2497.
26. Cesarini PR, Mendonça E, Fernandes V, Silva RC, Morimitsu LK, Gar-
cia FE, Vechiatti S, Miranda WL, Dib SA: Prevalence of immuno-
logic markers (Anti-GAD and Anti-IA2) in first-degree
relatives of patients with type 1 diabetes in the greater area
of São Paulo.  Rev Assoc Med Bras 2003, 49:395-400.
27. Kaisaki PJ, Menzel S, Lindner T, Oda N, Rjasanowski I, Sahm J,
Meincke G, Schulze J, Schmechel H, Petzold C, Ledermann HM,
Sachse G, Boriraj VV, Menzel R, Kerner W, Turner RC, Yamagata K,
Bell GI: Mutations in the hepatocyte nuclear factor-1alpha
gene in MODY and early-onset NIDDM: evidence for a muta-
tional hotspot in exon 4.  Diabetes 1997, 46:528-535.
28. Levy JC, Matthews DR, Hermans MP: Correct Homeostasis
Model Assessment (HOMA) evaluation uses the computer
program.  Diabetes Care 1998, 21:2191.
29. Yuan G, Al-Shali KZ, Hegele RA: Hypertriglyceridemia: its etiol-
ogy, effects and treatment.  CMAJ 2007, 176:1113-1120.
30. Anuradha S, Radha V, Deepa R, Hansen T, Carstensen B, Pedersen O,
Mohan V: Codon 98 (Ala98Val) of the Hepatocyte Nuclear
Factor-1alpha Is Associated With Maturity-Onset DiabetesPage 8 of 9
(page number not for citation purposes)
Cardiovascular Diabetology 2009, 8:28 http://www.cardiab.com/content/8/1/28Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
of the Young and Younger Age at Onset of Type 2 Diabetes
in Asian Indians.  Diabetes Care 2005, 28:2430-2435.
31. Hegele RA, Cao H, Harris SB, Hanley AJG, Zinman B, Connelly PW:
The Private Hepatocyte Nuclear Factor-1a G319S Variant Is
Associated With Plasma Lipoprotein Variation in Canadian
Oji-Cree.  Arterioscler Thromb Vasc Biol 2000, 20:217-222.
32. Gloyn AL: Glucokinase (GCK) mutations in hyper- and
hypoglycemia: maturity-onset diabetes of the young, perma-
nent neonatal diabetes, and hyperinsulinemia of infancy.
Hum Mutat 2003, 22:353-362.
33. Frequency Data for SNP rs1169288   [http://www.gene
cards.org/cgi-bin/snps/snp_link.pl?rs_number=1169288&file=/home/
genecards/versions/2.39build76/cards_usr/entries/HN/
card_HNF1A.txt;&kind=AlleleFreqData;&chrom=12]
34. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras
N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A,
Després JP: Hypertriglyceridemic Waist: A Marker of the
Atherogenic Metabolic Triad (Hyperinsulinemia; Hyperap-
olipoprotein B; Small, Dense LDL) in Men.  Circulation 2000,
102:179-184.
35. Ryffel GU: Mutations in the human genes encoding the tran-
scription factors of the hepatocyte nuclear factor (HNF)1
and HNF4 families: functional and pathological conse-
quences.  J Mol Endocrinol 2001, 27:11-29.
36. Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley
AT, Stoffel M: Regulation of Apolipoprotein M Gene Expres-
sion by MODY3 Gene Hepatocyte Nuclear Factor-1alpha.
Haploinsufficiency Is Associated With Reduced Serum Apol-
ipoprotein M Levels.  Diabetes 2003, 52:2989-2995.Page 9 of 9
(page number not for citation purposes)
